Start Date and Time
June 6, 2012 9:00 AM
End date and time
June 6, 2012 5:40 PM
(GMT-05:00) Eastern Time (US & Canada)
The University Club of New York
One West 54th Street
New York, NY 10019
Terry Koch or Kerry Iseman Registration options
Event registration is closed.
It is our great pleasure to invite you to attend the first
Financial Times U.S. Healthcare and Life Sciences Conference on June 6, 2012 in New York. Developed by the Financial Times (FT) in collaboration with Deloitte, this marks the first year of this event following the success of the FT’s Global Pharmaceutical and Biotechnology Conference that has been held in Europe for over 25 years.
Andrew Jack, Pharmaceuticals Correspondent of the Financial Times and R.T. (Terry) Hisey, Vice Chairman & US Life Sciences Leader, Deloitte Consulting LLP , this one-day conference will bring together an international line-up of industry experienced professionals/specialists, government decision-makers, and leading market commentators to review the shifting stands of the health care industry, and assess the bottom-line impacts and potential implications for business and commercial strategies.
2010 saw the passage into law of the milestone U.S. health care legislation, and the beginnings of a sweeping overhaul of the U.S. health care system. The potential implications for stakeholders across the entire health care continuum - for payers, for patients, and for providers as well as device manufacturers, life science companies and health care IT providers – can be profound. Yet the process of reform is likely fraught with political risk, with previously agreed exclusions such as government negotiations on pharma pricing, pay-for-delay, and drug reimportation now caught in the political crossfire. How can life science and health care companies manage for this uncertainty, and what may lie ahead of U.S. health care reform?
Confirmed speakers for this year’s conference include:
John Lechleiter, PhD, Chairman, President & CEO, Eli Lilly and Company
Heather Bresch, CEO, Mylan
Dr. Margaret A. Hamburg, Commissioner, U.S. Food and Drug Administration
Joe V. Selby, MD, M.P.H, Executive Director, Patient Centered Outcomes Research Institute
Kalipso Chalkidou, Director, NICE International
John Crowley, Chairman and Chief Executive Officer, Amicus Therapeutics
Geno Germano, President and General Manager, Specialty Care and Oncology, Pfizer Inc.
Nicholas Groombridge, Partner, Paul, Weiss, Rifkind, Wharton & Garrison LLP
R.T. (Terry) Hisey, Vice Chairman & US Life Sciences Leader, Deloitte LLP
Dr. Michael Kamarck, President, Merck BioVentures and SVP Vaccines and Biologics Manufacturing, Merck
Nancy Kelley, JD, MPP, Founding Executive Director, NY Genome Center
Ameet Mallik, Global Head of Sandoz Biopharmaceuticals & Oncology Injectables, Sandoz
Edward Michael, Executive Vice President, Diagnostics, Abbott Laboratories
David B. Nash, MD, MBA, Dean, Jefferson School of Population Health, Thomas Jefferson University
Daniel Palestrant, MD, Founder and CEO, Par8o, Inc.
Professor Guido Rasi, Executive Director, European Medicines Agency
George Scangos, PhD, Chief Executive Officer, Biogen Idec Topics of discussion include:
Delivering on the intent and potential of personalized medicine - what are the commercial models and strategies for the era of stratified medicine?
Biosimilars-coming of age?
A future based on value and outcomes - adjusting to the realities of Comparative Effectiveness Research (CER)
Social media and the age of health care consumerism
Remodeling the life sciences company for the 21st Century
As a part of Deloitte’s sponsorship of this event, you now can take advantage of a
25 percent discount off the event registration, please click here to register. Additional details and registration information can be found at http://www.ftconferences.com/ushc.
If you have any additional questions, please contact
Terry Koch or Kerry Iseman.
We look forward to welcoming you to the conference.
Event registration is closed.